2151. In Vitro Activity of Ceftazidime-Avibactam and Comparator Agents Against Pseudomonas aeruginosa Collected from Patients with Presumed Hospital- and Community-Acquired Respiratory Tract Infections: ATLAS Global Surveillance Program, 2017-2021

BACKGROUND: The β-lactamase inhibitor, avibactam, has potent inhibitory activity against Class A, Class C, and certain Class D serine β-lactamases. This study evaluated the in vitro activity of ceftazidime-avibactam (CZA) and comparators against respiratory tract infection (RTI)-associated Pseudomon...

Descripción completa

Detalles Bibliográficos
Autores principales: Wise, Mark G, Stone, Gregory, Sahm, Daniel F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678245/
http://dx.doi.org/10.1093/ofid/ofad500.1774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678245/
http://dx.doi.org/10.1093/ofid/ofad500.1774

Ejemplares similares